FindTrial
Sign In

The Efficacy and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in Preventing Postoperative Nausea and Vomiting in High-Risk Gynecological Laparoscopic Surgery Patients: A Randomized Controlled Trial

The Efficacy and Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in Preventing Postoperative Nausea and Vomiting in High-Risk Gynecological Laparoscopic Surgery Patients: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002486
Enrollment
Unknown
Registered
2025-12-24
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Sham stimulation group (group C):Sham stimulation mode
The taVNS group (T group):transcutaneous auricular vagus nerve stimulation

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1: Scheduled for elective gynecological laparoscopic surgery (e.g., hysterectomy, ovarian cystectomy) under general anesthesia at Zhejiang Provincial Hospital of Chinese Medicine. 2: Aged =18 and <65 years. 3: American Society of Anesthesiologists (ASA) physical status classification I-II. 4: Preoperative Apfel score = 2 points (The four primary predictors: female sex, non-smoker, postoperative opioid use, history of PONV or motion sickness). 5: Willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1: Cutaneous infection or deformity of the auricle (ear). 2: Severe hepatic or renal dysfunction, cardiovascular disease, or implanted cardiac pacemaker. 3: Severe autonomic nervous dysfunction or long-term use of medications affecting autonomic nerve function. 4: Use of antiemetic medications within 24 hours prior to surgery. 5: Known allergy to any drug involved in this study. 6: Pre-existing psychiatric disorders such as dementia. 7: Pregnant or lactating women. 8: Preoperative hemoglobin level below 9 g/dL. 9: Pre-existing significant gastrointestinal dysfunction, such as gastroparesis or intestinal obstruction.

Design outcomes

Primary

MeasureTime frame
Incidence of PONV within 24 hours after surgery;—

Secondary

MeasureTime frame
Postoperative nausea VAS score and vomiting times;The usage rate and dosage of remedial antiemetic drugs;Serum levels of gastrointestinal hormones and neurotransmitters;Changes in HRV indicators;Early postoperative recovery quality;—

Countries

China

Contacts

Public ContactWeiqiao Zhang

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

zwqmedical@163.com15268550747

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026